Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: lazar921 who wrote (6679)	1/12/1999 9:57:00 PM
From: BigKNY3	Respond to of 9523

Lazar, the entire Big Pharma sector is taking a hit. Wednesday's article on Big Pharma from S & P is posted below. Within 5 trading days (Monday is Martin Luther Kings' birthday), PFE will be announcing 4th Qt earnings and by the end of the month a stock split. Accordingly, expect more volatility and some great buying opportunities for bullish PFErs. Best of luck! BigKNY3 ________________________________________________ S&P MARKETSCOPE January 13, 1999 WEDNESDAY'S MARKETS: A LOOK AHEAD Despite Downturn, S&P Still Bullish on Drug Stocks Despite the recent weakness in drug stocks, we are still positive on the sector. Drug stocks have been negatively impacted by investor rotation from high-valuation defensive issues to cyclical stocks, based on the improving outlook for the U.S. stocks. Nevertheless, the fundamentals for the drug industry remain strong. We expect high double-digit Q4 earnings per share growth for the group, led by the projected Q4 EPS advance of over 40% for Warner-Lambert (WLA). We expect to see gains in the 20%-25% range for Pfizer Inc. (PFE), Eli Lilly (LLY), Schering-Plough (SGP), Pharmacia & Upjohn (PNU). Our favorites, all with five-star rankings (buy), are Warner Lambert (70 1/4), Pfizer (115 1/4), Merck & Co. (MRK; 148 1/8) and Bristol-Myers Squibb (BMY; 129).